Evidence map›Paper›PMID 41152832›Full record

ArticleBMC public health2025

Multilevel drivers of tobacco use among people living with HIV in West Nile and Karamoja Regions in Uganda: a mixed-methods study.

Ezekiel Musasizi, Heather Wipfli, Jim Arinaitwe, Lynn Atuyambe, Kyra Guy, Ronald Kusolo, Elizeus Rutebemberwa, David Guwatudde

Abstract read
In one paragraph

Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ezekiel MusasiziSchool of Public Health, Makerere University, Centre for Tobacco Control in Africa, Kampala, Uganda. emusasizi@ctc-africa.org.
Heather WipfliKeck School of Medicine, Department of Preventative Medicine, University of Southern California, Los Angeles, CA, USA.
Jim ArinaitweSchool of Public Health, Makerere University, Centre for Tobacco Control in Africa, Kampala, Uganda.
Lynn AtuyambeSchool of Public Health, Department of Community Health and Behavioural Sciences, Makerere University, Kampala, Uganda.
Kyra GuyKeck School of Medicine, Department of Preventative Medicine, University of Southern California, Los Angeles, CA, USA.
Ronald KusoloSchool of Public Health, Makerere University, Centre for Tobacco Control in Africa, Kampala, Uganda.
Elizeus RutebemberwaSchool of Public Health, Department of Health Policy, Planning, and Management, Makerere University, Kampala, Uganda.
David GuwatuddeDepartment of Epidemiology and Biostatistics, Makerere University School of Public Health, Kampala, Uganda.

Funding

Understanding Stigma as a barrier to cancer prevention and treatment in Uganda and ZambiaU01CA261624 · NCI · UNIV OF MARYLAND, COLLEGE PARK · PI WIPFLI, HEATHER L · 2021 to 2025
$3.7M
Makerere University Research and Innovation Fund Round 5National Cancer Institution U01CA261624 (PI: Wipfli)NCI NIH HHS U01 CA261624
6 · The paper itself

Abstract

backgroundTobacco use is a significant public health problem, especially among People Living with HIV (PLWH) yet evidence on its prevalence and multi-level drivers in Uganda remains limited. This study assessed the prevalence and multilevel drivers of tobacco use among PLWH in two regions in northern Uganda.

methodsWe conducted a mixed-methods study involving a survey of 439 PLWH randomly sampled from eight health facilities in West Nile and Karamoja regions and Focus Group Discussion (FGDs) of 47 PLWH to understand multi-level drivers of tobacco use. Data was collected from August 15th to December 20th, 2024. Survey data was collected electronically using Open Data Kit (ODK) platform. Tobacco use was biochemically verified using cotinine urine dipsticks. We conducted quantitative analysis to identify factors associated with tobacco use using multinomial regression model using STATA v14. Qualitative data was analyzed using thematic analysis in NVivo V15.

resultsAccording to self-reports, Tobacco use was more prevalent in Karamoja than in West Nile, with smokeless tobacco dominating in Karamoja and smoking more common in West Nile. Nicotine dependence was higher among smokers (49.1%) than smokeless users (32.1%). Smoking was associated with being male (RRR = 11.13; 95% CI, 5.08-24.41) and having lower tobacco realted - knowledge (RRR = 0.39; 95% CI, 0.17-0.90). Smokeless tobacco use was associated with district of residence (RRR = 177.57; 95% CI, 29.36-1074.02) and other substance use (RRR = 4.08; 95% CI, 1.06-15.64). FGDs revealed multi-level drivers spanning the intrapersonal level (addiction, HIV-related distress, gender norms, and limited knowledge), interpersonal level (peer and family influence), community level (cultural practices and stigma), organizational level (tobacco affordability and inadequate cessation services), and the policy level, where limited awareness and weak enforcement of existing smokeless tobacco regulations contributed to continued use of tobacco.

conclusionTobacco cessation strategies should be mode-specific and context-sensitive. In West Nile, where smoking and dual use are common, interventions should target men with low tobacco-related knowledge. In Karamoja, where smokeless tobacco is culturally entrenched and enforcement of existing bans is weak, cessation requires community-based education, facility-based treatment, and post-care support. Addressing multi-level drivers is essential for tobacco use cessation among PLWH in similar settings.

Indexed as

HIV InfectionsTobacco UseAdultFemaleFocus GroupsHumansMaleMiddle AgedPrevalenceSurveys and QuestionnairesTobacco, SmokelessUgandaYoung AdultHIV, UgandaSmokeless tobacco useSmokingTobacco use

Identifiers

PMID41152832
PMCPMC12560500

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.